[Phase II study of @entity3003 in @entity5464 . Urological Cooperative Study Group on XXXX ].

@entity1 @entity8 @entity263 @entity390 @entity2167 @entity882 @entity5 @entity3003 @entity5464 @entity900 @entity391 @entity1606 @entity1431 @entity4797
@entity3003 was evaluated in a phase II study involving 109 @entity1 with @entity5464 . A total of 21 cases of advanced @entity5 , 38 of @entity1606 ( @entity1606 ) of the urinary tract and 25 of @entity263 were evaluable for response. The response rate in @entity5 was 48%, with 70% in @entity4797 and 27% in nonseminomas. Three responses were observed in @entity1 previously treated with @entity900 . In @entity1606 , the response rate was 18%. No response was observed in @entity263 . @entity3003 was well tolerated with no significant @entity8 and @entity2167 detected. @entity390 and @entity391 were experienced by 50% of @entity1 but the severity was low. Severe myelosuppression, @entity882 and @entity1431 were observed. In conclusion, @entity3003 has demonstrated activity in both @entity5 and @entity1606 of the urinary tract and is worthy of further study, especially in combination with other active drugs.
